Revolution Medicines, Inc.
RVMD
$74.74
-$0.58-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 262.51M | 19.13M | 205.75M | 188.10M | 151.75M |
| Gross Profit | -262.51M | -19.13M | -205.75M | -188.10M | -151.75M |
| SG&A Expenses | 52.76M | 40.58M | 35.01M | 28.21M | 23.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 315.27M | 264.71M | 240.76M | 216.31M | 175.71M |
| Operating Income | -315.27M | -264.71M | -240.76M | -216.31M | -175.71M |
| Income Before Tax | -305.21M | -247.79M | -213.42M | -195.32M | -156.29M |
| Income Tax Expenses | -- | -- | -- | -753.00K | -- |
| Earnings from Continuing Operations | -305.21M | -247.79M | -213.42M | -194.57M | -156.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -305.21M | -247.79M | -213.42M | -194.57M | -156.29M |
| EBIT | -315.27M | -264.71M | -240.76M | -216.31M | -175.71M |
| EBITDA | -313.24M | -262.89M | -239.10M | -214.61M | -174.10M |
| EPS Basic | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 |
| Normalized Basic EPS | -1.01 | -0.82 | -0.71 | -0.70 | -0.59 |
| EPS Diluted | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 |
| Normalized Diluted EPS | -1.01 | -0.82 | -0.71 | -0.70 | -0.59 |
| Average Basic Shares Outstanding | 189.23M | 188.58M | 188.15M | 173.76M | 166.84M |
| Average Diluted Shares Outstanding | 189.23M | 188.58M | 188.15M | 173.76M | 166.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |